A new study highlights that U.S. Food and Drug Administration (FDA) officials
tasked with approving new drugs often move on to work in the pharmaceutical
industry. The so-called “revolving door” raises concerns about
The researchers examined the FDA hematology-oncology drug approvals listed
on the agency’s website to identify 55 unique medical reviewers
from 2001 to 2010. They then searched publicly available information from
the Department of Health and Human Services, LinkedIn, and PubMed to ascertain
their subsequent jobs.
The results, which were published in the
British Medical Journal, confirmed that the revolving door may be busier than many suspected.
Of the 26 reviewers who left the FDA, more than half (57.7 percent) later
worked for the biopharmaceutical industry or consulted to it. Overall,
approximately 27 percent of the total number of reviewers left their regulatory
posts to work for the industry that they were previously tasked with overseeing.
Given that drug reviewers play an essential role in protecting patients
from ineffective and harmful drugs, the results are concerning.
“If you know in the back of your mind that your career goal may be
to someday work on the other side of the table, I wonder whether that
changes the way you regulate,” Dr. Vinay Prasad, the study’s
lead researcher, stated. “Are you more likely to give [companies]
the benefit of the doubt? Are you less likely to beat them up hard over
[using bad comparisons in drug studies]?”
If you or someone you care about has suffered serious harm due to a dangerous
or defective drug or medical device, don’t hesitate to contact
a San Diego injury lawyer at the Law Offices of Robert Vaage for a free
consultation. Our legal team has successfully represented clients against
manufacturers and distributors of medical devices for more than 30 years.